Angela von Czarnecki, Technical Support Scientist @ Somalogic
SomaLogic, a part of Standard BioTools, is catalysing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 11,000 protein measurements, covering half the human proteome. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. In today’s seminar, we have Angela Von Czarnecki (Technical support Scientist) from SomaLogic to explain how the SomaScan assay works and how it is currently being used in oncology to discover biomarkers relevant to diagnosis, disease severity, and treatment decision-making.
These papers and more will be discussed in this seminar.
- Gupta, S., Westacott, M.J., Ayers, D.G. et al. Plasma proteome of growing tumors. Sci Rep 13, 12195 (2023). https://doi.org/10.1038/s41598-023-38079-9
- Ben Yellin, Lahav C, Sela I, et al. Analytical validation of the PROphet test for treatment decision-making guidance in metastatic non-small cell lung cancer. J Pharm Biomed Anal. 2024;238:115803. doi:10.1016/j.jpba.2023.115803
About the Presenter:
Angela joined Somalogic in 2023 as part of the Global Scientific Engagement team and has close to 15 years of experience in utilizing high throughput proteomics and genomics methodology. She has specialised knowledge in both reproductive health and oncology and has supported customer in both research and clinical settings to achieve their goals.
In her current role she is helping to bring awareness to this ‘next generation’ of high throughput proteomic technologies and help customers design their studies to generate new insights into their disease of interest.
